Amlexanox for Type 2 Diabetes and Obesity
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01842282 |
Recruitment Status
:
Active, not recruiting
First Posted
: April 29, 2013
Last Update Posted
: November 6, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus Type 2 Non Alcoholic Fatty Liver Disease Obesity | Drug: Amlexanox | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics |
Actual Study Start Date : | July 19, 2013 |
Estimated Primary Completion Date : | October 2019 |
Estimated Study Completion Date : | December 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Amlexanox |
Drug: Amlexanox
Other Name: Solfa tablets
|
- HbA1c [ Time Frame: 12 weeks ]improvement in HbA1c
- hepatic steatosis by MRI [ Time Frame: 12 weeks ]improvement in hepatic steatosis by MRI
- Weight [ Time Frame: 12 weeks ]weight decrease

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 59 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ≥ 18 years old at baseline and <60 years of age.
-
Is male, female not of childbearing potential, or meets all the following criteria if female of childbearing potential (including perimenopausal women who have had a menstrual period within one year):
- Not breastfeeding.
- Negative pregnancy test result (human chorionic gonadotropin, beta subunit [βhCG]) at baseline (not applicable to hysterectomized females).
- Must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate when use consistently and correctly, such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire duration of study period.
- Has physician-confirmed diabetes mellitus with a clear diagnosis or per ADA criteria with fasting glucose>126 mg/dL or HbA1c >6.4% or 2 hour GTT >200 mg/dL or or pre-diabetes with fasting glucose >100 mg/dL (n= up to 8)
- BMI ≥27 and <36 kg/m2.
- On no medications or only on first line oral medications (such as Metformin and/or DPP IV inhibitors) for treatment of type 2 diabetes mellitus with a stable regimen for >12 weeks.
- Alcohol consumption of less than 40 grams/week.
- A liver US confirming presence of fatty infiltration of the liver.
- Is able to read, understand and sign the U of M IRBMED approved informed consent form (ICF), communicate with study physician and study team, understand and comply with protocol requirements.
Exclusion Criteria:
- On insulin, sulfonylurea or other injectables for treatment of type 2 diabetes
- Unable to conduct home based glucose monitoring
- HbA1c>9.5%
- Presence of advanced liver disease (as evidenced by abnormal synthetic function, abnormal PT or albumin).
- Evidence of other etiologies of viral hepatitis.
- Presence of hematologic, bone marrow and/or other abnormalities.
- Presence of hemoglobinopathy or other hematological abnormalities that will interfere with accurate measurement of HbA1c
- Presence of HIV infection.
- Inability to give informed consent.
- Presence of ESRD, any type of active cancer, or >class 2 congestive heart failure (New York Heart Association Functional Classification System), based on medical history and physical examination.
- Active chronic infection such as known chronic osteomyelitis or tb, etc. (may be transient).
- Creatinine >1.5 mg/dL
- Proliferative diabetic retinopathy, nonproliferative retinopathy is allowed
- Unable to ambulate
- Clinically relevant CAD: history of stent, CABG or cardiologist confirmed angina
- Any other condition in the opinion of the investigators that may impede successful data collection.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01842282
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | Elif A Oral, MD | Univeristy of Michigan |
Responsible Party: | Elif Oral, Associate Professor of Medicine, University of Michigan |
ClinicalTrials.gov Identifier: | NCT01842282 History of Changes |
Other Study ID Numbers: |
HUM00065177 |
First Posted: | April 29, 2013 Key Record Dates |
Last Update Posted: | November 6, 2017 |
Last Verified: | October 2017 |
Studies a U.S. FDA-regulated Drug Product: | Yes | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Elif Oral, University of Michigan:
diabetes mellitus type 2 non alcoholic fatty liver disease obesity amlexanox |
Additional relevant MeSH terms:
Diabetes Mellitus Obesity Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Digestive System Diseases Amlexanox Anti-Allergic Agents |